OP-101 for COVID-19

OP-101 for COVID-19

OP-101 selectively targets reactive macrophages responsible for hyperinflammation leading to lung injury and multi-organ failure in severe COVID-19 patients.

OP-101 has completed two human safety studies at doses 5-10-fold higher than proposed doses in our Phase 2 study in severe COVID-19 patients.

OP-101 Mechanism of Action to Address Hyperinflammation in Severe COVID-19 Patients